Trial Profile
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Head and neck cancer; Salivary gland cancer; Skin cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 20 Sep 2023 Planned End Date changed from 31 Dec 2024 to 31 Mar 2025.
- 20 Sep 2023 Planned primary completion date changed from 31 Dec 2024 to 31 Mar 2025.
- 07 Sep 2023 Planned End Date changed from 31 Mar 2025 to 31 Dec 2024.